Cargando…

Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study

There has been a marked increase in the use of low-dose computed tomography (LDCT) for lung cancer screening. However, the potential of LDCT to predict metabolic syndrome (MetS) has not been well-documented in this risk-sharing population. We assessed the reliability of epicardial fat volume (EFV) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyun Ji, Lee, Heon, Lee, Bora, Lee, Jae Wook, Shin, Kyung Eun, Suh, Jon, Park, Hyun Woo, Kim, Jeong A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407965/
https://www.ncbi.nlm.nih.gov/pubmed/30762814
http://dx.doi.org/10.1097/MD.0000000000014601
_version_ 1783401665651539968
author Kim, Hyun Ji
Lee, Heon
Lee, Bora
Lee, Jae Wook
Shin, Kyung Eun
Suh, Jon
Park, Hyun Woo
Kim, Jeong A.
author_facet Kim, Hyun Ji
Lee, Heon
Lee, Bora
Lee, Jae Wook
Shin, Kyung Eun
Suh, Jon
Park, Hyun Woo
Kim, Jeong A.
author_sort Kim, Hyun Ji
collection PubMed
description There has been a marked increase in the use of low-dose computed tomography (LDCT) for lung cancer screening. However, the potential of LDCT to predict metabolic syndrome (MetS) has not been well-documented in this risk-sharing population. We assessed the reliability of epicardial fat volume (EFV) and epicardial fat area (EFA) measurements on chest LDCT for prediction of MetS. A total of 130 (mean age, 50.2 ± 10.77 years) asymptomatic male who underwent nonelectrocardiography (ECG)-gated LDCT were divided into 2 groups for the main analysis (n = 75) and validation (n = 55). Each group was further divided into subgroups with or without MetS. EFV and EFA were calculated semiautomatically using commercially available software with manual assistance. The area under the curve (AUC) on receiver operating characteristic (ROC) analysis and cutoff values to predict MetS on LDCT were then calculated and validated. Female data were not available for analysis due to small sample size in this self-referred lung cancer screening program. In the analysis group, the mean EFV was 123.12 ± 42.29 and 67.30 ± 20.68 cm(3) for the MetS and non-MetS subgroups, respectively (P < .001), and the mean EFA was 7.95 ± 3.10 and 4.04 ± 1.73 cm(2), respectively (P < .001). Using 93.65 and 4.94 as the cutoffs for EFV and EFA, respectively, the sensitivity, specificity, positive and negative predictive values, and accuracy for predicting MetS were 84.2% and 84.2%, and 92.9% and 64.3% (P < .001); 80% and 44.4% (P = .01); 94.5% and 92.3%; and 90.7% and 69.3% (P < .001), respectively. The AUC for EFV and EFA for predicting MetS was 0.909 and 0.808 (95% confidence interval, 0.819–1.000 and 0.702–0.914, respectively) (P = .02). Using the same cutoff values in the analysis group, there was no significant difference in diagnostic performance using EFV and EFA between the analysis and validation sets. Although quantification of both EFA and EFV is feasible on non-ECG-gated LDCT, EFV may be used to reliably predict MetS with fairly high and better diagnostic performance in selected population.
format Online
Article
Text
id pubmed-6407965
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64079652019-03-16 Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study Kim, Hyun Ji Lee, Heon Lee, Bora Lee, Jae Wook Shin, Kyung Eun Suh, Jon Park, Hyun Woo Kim, Jeong A. Medicine (Baltimore) Research Article There has been a marked increase in the use of low-dose computed tomography (LDCT) for lung cancer screening. However, the potential of LDCT to predict metabolic syndrome (MetS) has not been well-documented in this risk-sharing population. We assessed the reliability of epicardial fat volume (EFV) and epicardial fat area (EFA) measurements on chest LDCT for prediction of MetS. A total of 130 (mean age, 50.2 ± 10.77 years) asymptomatic male who underwent nonelectrocardiography (ECG)-gated LDCT were divided into 2 groups for the main analysis (n = 75) and validation (n = 55). Each group was further divided into subgroups with or without MetS. EFV and EFA were calculated semiautomatically using commercially available software with manual assistance. The area under the curve (AUC) on receiver operating characteristic (ROC) analysis and cutoff values to predict MetS on LDCT were then calculated and validated. Female data were not available for analysis due to small sample size in this self-referred lung cancer screening program. In the analysis group, the mean EFV was 123.12 ± 42.29 and 67.30 ± 20.68 cm(3) for the MetS and non-MetS subgroups, respectively (P < .001), and the mean EFA was 7.95 ± 3.10 and 4.04 ± 1.73 cm(2), respectively (P < .001). Using 93.65 and 4.94 as the cutoffs for EFV and EFA, respectively, the sensitivity, specificity, positive and negative predictive values, and accuracy for predicting MetS were 84.2% and 84.2%, and 92.9% and 64.3% (P < .001); 80% and 44.4% (P = .01); 94.5% and 92.3%; and 90.7% and 69.3% (P < .001), respectively. The AUC for EFV and EFA for predicting MetS was 0.909 and 0.808 (95% confidence interval, 0.819–1.000 and 0.702–0.914, respectively) (P = .02). Using the same cutoff values in the analysis group, there was no significant difference in diagnostic performance using EFV and EFA between the analysis and validation sets. Although quantification of both EFA and EFV is feasible on non-ECG-gated LDCT, EFV may be used to reliably predict MetS with fairly high and better diagnostic performance in selected population. Wolters Kluwer Health 2019-02-15 /pmc/articles/PMC6407965/ /pubmed/30762814 http://dx.doi.org/10.1097/MD.0000000000014601 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Kim, Hyun Ji
Lee, Heon
Lee, Bora
Lee, Jae Wook
Shin, Kyung Eun
Suh, Jon
Park, Hyun Woo
Kim, Jeong A.
Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title_full Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title_fullStr Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title_full_unstemmed Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title_short Diagnostic value of using epicardial fat measurement on screening low-dose chest CT for the prediction of metabolic syndrome: A cross-validation study
title_sort diagnostic value of using epicardial fat measurement on screening low-dose chest ct for the prediction of metabolic syndrome: a cross-validation study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407965/
https://www.ncbi.nlm.nih.gov/pubmed/30762814
http://dx.doi.org/10.1097/MD.0000000000014601
work_keys_str_mv AT kimhyunji diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT leeheon diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT leebora diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT leejaewook diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT shinkyungeun diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT suhjon diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT parkhyunwoo diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy
AT kimjeonga diagnosticvalueofusingepicardialfatmeasurementonscreeninglowdosechestctforthepredictionofmetabolicsyndromeacrossvalidationstudy